A new study published in the Journal of the American Medical Association finds that doctors are influenced by gifts and their relationships with drug company representatives. Read More »
Drug Channels, a website providing expert insights on pharmaceutical economics and the drug distribution system, recently commented on a new report from the Centers for Medicare & Medicaid Services, titled “Medicare Part D – Direct and Indirect Remuneration.” Read More »
Sandoz has introduced the authorized generic version of Alcon Research Ltd.'s Pataday, an olopatadine hydrochloride ophthalmic solution. Read More »
Omnicell Inc. announced an agreement with CompleteRX to develop a medication distribution model for the Commonwealth of Massachusetts State Office of Pharmacy Services. Read More »
Global generic pharmaceutical giant Teva recently released its generic version of Zetia (ezetimibe) in 10mg tablets to address total and low-density lipoprotein (LDL) blood cholesterol levels for U.S. patients, company officials announced from Jerusalem headquarters. Read More »
After documenting recent product abuse, the U.S. Food and Drug Administration asked Endo Pharmaceuticals to voluntarily remove its reformulated Opana ER (oxymorphone hydrochloride) opioid medication from circulation, stating that risks may now outnumber benefits. Read More »
Alkermes PLC’s Aristada (aripiprazole lauroxil) injectable medication has won approval from the U.S. Food and Drug Administration as an extended-release injectable suspension to treat schizophrenia. Read More »
Sanofi Pasteur's Quadracel vaccine has been approved by the U.S. Food and Drug Administration to protect children between the ages of 4 and 6 against diphtheria, tetanus, pertussis and poliomyelitis. Read More »
Astellas, a global pharmaceutical corporation with U.S. headquarters in Northbrook, Illinois, and biotechnology company Seattle Genetics recently publicized findings on their enfortumab vedotin (ASG-22ME) treatment for a type of cancer commonly manifesting in the bladder. Read More »
ReachBio Research Labs recently announced that it launched cellPrism, a drug development platform designed to deliver a spectrum of customized in-vitro assays to biotechnology and pharmaceutical companies. Read More »
OneOme, the company behind the OneOme RightMed pharmacogenomics test, recently delivered a statement about how DNA has the power to minimize medication trial and error and help people with heart conditions improve their cardiovascular treatments. Read More »
Enanta Pharmaceuticals Inc.'s New Drug Application (NDA) for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), developed in conjunction with AbbVie, has been accepted by the U.S Food and Drug Administration. Read More »
The American Pharmacists Association (APA) recently announced that new research shows adding 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy led to an increase in survival rates and for patients with recurrent prostate cancer. Read More »
Daiichi Sankyo Inc. will take the helm on handling U.S. commercialization of the FDA-approved RoxyBond (oxycodone hydrochloride) oral-use medication manufactured by Inspirion Delivery Sciences LLC, the companies announced recently from their respective New Jersey hubs. Read More »
The Health Affairs Blog, a vehicle for commentary on health policy and issues, recently wrote about how the Cures Act and FDA Draft Guidance suggest flexibility on communication of real-world drug impacts. Read More »
Amgen's Fourier trial for Repatha met its primary composite endpoint and the key secondary composite endpoint. Read More »
CVS Health has released an article about making it easier for patients to prevent and manage chronic disease. Read More »
Spinraza (nusinersen) recently won European Commission authorization to treat 5q SMA — the most common form of spinal muscular atrophy — becoming the first such drug to achieve European approval, manufacturer Biogen announced from Cambridge, Massachusetts. Read More »
Express Scripts has released its 2016 Drug Trend Report for the commercial market. Read More »
Trumenba, Pfizer’s branded vaccine against certain forms of meningococcal disease, officially won approval from the European Commission for patients aged 10 years and up, representing progress for protection in the young adult demographic. Read More »
Alerts Sign-up
